Please assess the completion status of the following clinical trial:

Trial Title: Vinpocetine Inhibits NF-κB-dependent Inflammation in Acute Ischemic Stroke Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \>18 years of age~* Anterior-circulation ischemic stroke: All patients had symptoms of focal neurological deficits and simultaneous radiological evidence (magnetic resonance imaging, MRI) of an ischemic brain lesion~* measurable neurological deficit (NIHSS \> 5)~* interval between symptom onset and admission more than 4.5 hours and less than 48 hours. That is, all patients we recruited were beyond the 4.5 hours of symptom onset and, therefore, past the accepted time-window for thrombolytic therapy~Exclusion Criteria:~* hemorrhagic stroke and severe hemorrhage in other organs~* other diseases of the central nervous system (CNS)~* diabetes mellitus~* tumor or hematological systemic diseases~* any infection before acute ischemic stroke~* concomitant use of antineoplastic or immune modulating therapies~* contraindication to MRI

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- vinpocetine group (Type: ACTIVE_COMPARATOR): Aspirin, 10mg, po and 30 mg of the vinpocetine by intravenous infusion once daily, for fourteen consecutive days
- Control group (Type: PLACEBO_COMPARATOR): Patients will receive aspirin only.

Based on this trial design, predict the completion outcome and termination type (if applicable).